- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07951398
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Young Children With Functional Constipation: a Prospective Comparative Study (BC-LGG-FC)
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Children Aged 12-48 Months With Functional Constipation: A Prospective, Open-Label, Three-Arm Comparative Study
This prospective study compared Bacillus clausii and Lactobacillus rhamnosus GG, each added to dietary management, with dietary management alone in children aged 12-48 months with functional constipation (Rome IV). Children assigned to probiotic treatment were randomly allocated to Bacillus clausii or Lactobacillus rhamnosus GG (2 × 10⁹ spores or CFU daily for two months); consecutive children receiving dietary management alone served as controls. Defecation frequency, stool consistency, painful defecation and abdominal distension were assessed at baseline and at months 1 and 2.
Visão geral do estudo
Status
Condições
Descrição detalhada
This prospective, open-label, three-arm comparative study was conducted at the pediatric gastroenterology outpatient clinic of Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, between February 2020 and July 2021.
Allocation: Children assigned to probiotic treatment were randomly allocated in a 1:1 ratio to the Bacillus clausii (BC) or Lactobacillus rhamnosus GG (LGG) group according to a computer-generated randomization list. The control group consisted of consecutive eligible children who presented during the same period and received dietary management alone; this group was not part of the randomization. No placebo was used, and caregivers and investigators were aware of group assignment.
Interventions: Children in the BC group received an oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial (Enterogermina®, Sanofi S.p.A., Italy), one vial once daily. Children in the LGG group received oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops (Maflor®, Mamsel İlaç San. ve Tic. A.Ş., Türkiye), 12 drops once daily (2 × 10⁹ CFU/day). Both probiotics were administered for two months. All children, including those in the control group, received an individualized, age- and weight-appropriate fiber-rich diet plan together with advice on age-appropriate fluid intake. No laxatives or other pharmacological treatments for constipation were given.
Assessments: Weekly defecation frequency (caregiver stool diary), stool consistency (modified Bristol Stool Form Scale for children), painful defecation and abdominal distension were recorded at baseline and at months 1 and 2. Adherence to the probiotic and dietary recommendations was assessed by caregiver report at each follow-up visit.
Outcomes: The primary outcomes were weekly defecation frequency and the presence of painful defecation at month 2. Secondary outcomes were weekly defecation frequency at month 1, stool consistency at months 1 and 2, painful defecation at month 1 and abdominal distension at months 1 and 2.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Istanbul, Turquia (Türkiye), 34295
- Department of Pediatrics, Faculty of Medicine, Biruni University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 12 to 48 months
- Functional constipation according to the Rome IV criteria for infants and toddlers (criterion G7): at least two of the following for at least one month: two or fewer defecations per week; history of excessive stool retention; history of painful or hard bowel movements; history of large-diameter stools; presence of a large fecal mass in the rectum. In toilet-trained children, at least one episode per week of incontinence after the acquisition of toileting skills and a history of large-diameter stools that may obstruct the toilet were also considered.
- Written informed consent from a parent or legal guardian
Exclusion Criteria:
- Organic cause of constipation (Hirschsprung disease, anorectal malformation, hypothyroidism, celiac disease, or a spinal or neuromuscular disorder)
- Developmental delay
- Previous gastrointestinal surgery
- Use of probiotics, laxatives or antibiotics within the preceding 8 weeks
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Bacillus clausii + dietary management
Bacillus clausii oral suspension, 2 × 10⁹ spores (one 5-mL vial) once daily for 2 months, in addition to individualized dietary management. |
Oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial; one vial once daily for 2 months.
Outros nomes:
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
|
Experimental: Lactobacillus rhamnosus GG + dietary management
Lactobacillus rhamnosus GG oral drops, 2 × 10⁹ CFU (12 drops) once daily for 2 months, in addition to individualized dietary management. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. Oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops; 12 drops once daily (2 × 10⁹ CFU/day) for 2 months.
Outros nomes:
|
|
Comparador Ativo: Dietary management alone
Individualized dietary management without a probiotic. Consecutive eligible children presenting during the same period; not randomized. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Weekly defecation frequency
Prazo: 2 months after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
2 months after the start of treatment
|
|
Proportion of children with painful defecation
Prazo: 2 months after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit |
2 months after the start of treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Weekly defecation frequency
Prazo: 1 month after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
1 month after the start of treatment
|
|
Stool consistency (modified Bristol Stool Form Scale for children)
Prazo: 1 month and 2 months after the start of treatment
|
Caregiver-rated stool form using the modified Bristol Stool Form Scale for children; higher scores indicate softer stools. |
1 month and 2 months after the start of treatment
|
|
Proportion of children with painful defecation
Prazo: 1 month after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit. |
1 month after the start of treatment
|
|
Proportion of children with abdominal distension
Prazo: 1 month and 2 months after the start of treatment
|
Presence or absence of abdominal distension, assessed at the follow-up visit. |
1 month and 2 months after the start of treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: ABDULLAH SERT, Department of Pediatrics, Faculty of Medicine, Biruni University
Publicações e links úteis
Publicações Gerais
- Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print.
- Lane MM, Czyzewski DI, Chumpitazi BP, Shulman RJ. Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr. 2011 Sep;159(3):437-441.e1. doi: 10.1016/j.jpeds.2011.03.002. Epub 2011 Apr 13.
- Lojanatorn P, Phrommas J, Tanpowpong P, Getsuwan S, Lertudomphonwanit C, Treepongkaruna S. Efficacy of Bacillus clausii in Pediatric Functional Constipation: A Pilot of a Randomized, Double-Blind, Placebo-Controlled Trial. Indian Pediatr. 2023 Jun 15;60(6):453-458. Epub 2023 Feb 9.
- Gordon M, de Geus A, Boruta M, Banasiuk M, Benninga M, Borrelli O, Darbari A, Dore-Stites D, Gould M, Hawa J, Jones K, Kilgore A, Mousa H, Nurko S, Thapar N, Khlevner J, Sinopoulou V, Tabbers M. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years. J Pediatr Gastroenterol Nutr. 2026 Aug;83(2):335-366. doi: 10.1002/jpn3.70447. Epub 2026 May 20.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- KAEK-151-2019
- Ethics decision 151/2019 (Outro identificador: Taksim Training and Research Hospital Clinical Research Ethics Committee)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data underlying the reported results will be available from the corresponding author upon reasonable request.
Prazo de Compartilhamento de IPD
Beginning after publication of the article, with no planned end date.
Critérios de acesso de compartilhamento IPD
De-identified individual participant data underlying the reported results will be available to researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author (asert@biruni.edu.tr); data will be shared after approval of the request and a data-sharing agreement.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .